Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
GlobeNewswire
· SIMLANDI is the first interchangeable high-concentration, citrate-free biosimilar to Humira^®REYKJAVIK, Iceland and PARSIPPANY,..
· SIMLANDI is the first interchangeable high-concentration, citrate-free biosimilar to Humira^®REYKJAVIK, Iceland and PARSIPPANY,..
· Alvotech, in agreement with Teva Pharmaceuticals, has signed an agreement with a strategic partner to bring to the U.S. market..
· Total Revenues in 2023 were $93.4 million, up 10% from previous year
· Product Revenues in 2023 were $48.7 million,..